Liquidia Technologies Shares Outstanding 2018-2020 | LQDA

Liquidia Technologies shares outstanding from 2018 to 2020. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Liquidia Technologies Annual Shares Outstanding
(Millions of Shares)
2019 18
2018 7
2017 1
Liquidia Technologies Quarterly Shares Outstanding
(Millions of Shares)
2020-09-30 38
2020-06-30 28
2020-03-31 28
2019-12-31 18
2019-09-30 19
2019-06-30 19
2019-03-31 16
2018-12-31 7
2018-09-30 11
2018-06-30 1
2018-03-31 1
2017-12-31
2017-09-30 1
2017-06-30 1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.149B $0.001B
Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29